论文部分内容阅读
目的观察阿托伐他汀治疗冠心病合并高脂血症的临床疗效。方法选取2010年9月—2015年2月在内蒙古医科大学附属医院治疗的冠心病合并高脂血症患者102例,采用随机数字法分为对照组和观察组,各51例。两组患者均进行常规治疗,对照组患者在此基础上加用血脂康胶囊,观察组患者在此基础上加用阿托伐他汀钙片,连续治疗8周后比较两组患者临床疗效、血脂指标、心功能指标、心绞痛以及不良反应发生情况。结果观察组患者临床疗效优于对照组(u=2.613,P=0.009)。观察组患者左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)短于对照组,左心室射血分数(LVEF)高于对照组(P<0.05)。两组患者治疗前血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)比较,差异无统计学意义(P>0.05);观察组患者治疗后血清TC、TG、LDL-C水平低于对照组,血清HDL-C水平高于对照组(P<0.05)。两组患者治疗前心绞痛发作次数、发作持续时间比较,差异无统计学意义(P>0.05);观察组患者治疗后心绞痛发作次数少于对照组,发作持续时间短于对照组(P<0.05)。两组患者均未发生与药物相关的明显肝肾功能损伤、肌溶解等严重不良反应;两组患者腹泻、呕吐及肌肉疼痛等轻度不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿托伐他汀治疗冠心病合并高脂血症安全、有效,能够有效改善患者心功能,控制血脂,降低心绞痛发生次数及缩短发作持续时间。
Objective To observe the clinical efficacy of atorvastatin in the treatment of coronary heart disease complicated with hyperlipidemia. Methods From September 2010 to February 2015, 102 patients with coronary heart disease complicated with hyperlipidemia treated in the Affiliated Hospital of Inner Mongolia Medical University were randomly divided into control group and observation group with 51 cases in each group. The two groups of patients were treated routinely. The patients in the control group were given Xuezhikang capsule on this basis. The patients in the observation group were given atorvastatin calcium tablets on this basis. After 8 weeks of continuous treatment, the clinical curative effect, Indicators, cardiac function, angina pectoris and adverse reactions. Results The clinical efficacy of the observation group was better than that of the control group (u = 2.613, P = 0.009). The left ventricular end-diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD) in observation group were shorter than those in control group, and left ventricular ejection fraction (LVEF) was higher than that in control group (P <0.05). There were no significant differences in serum TC, TG, LDL-C and HDL-C before treatment in both groups (P> 0.05). The levels of TC, TG and LDL-C in the observation group were lower than those in the control group, and the serum HDL-C level was higher than that in the control group (P <0.05). There was no significant difference in the number of episodes of angina pectoris and duration of seizures between the two groups before treatment (P> 0.05). The number of angina pectoris in observation group was less than that in control group, and the duration of seizure was shorter than that in control group (P <0.05) . There were no significant adverse drug reactions such as liver injury and liver dysfunction and muscular lysis in both groups. There was no significant difference in incidence of mild adverse reactions such as diarrhea, vomiting and muscle pain between the two groups (P> 0.05 ). Conclusion Atorvastatin treatment of coronary heart disease with hyperlipidemia is safe and effective, can effectively improve the patient’s cardiac function, blood lipid control, reduce the incidence of angina and shorten the duration of the attack.